The value of multiparametric magnetic resonance imaging in predicting IDH1 R132H mutation status in adult gliomas
Main Article Content
Abstract
Glioma is the most common primary tumor of adult central nervous system. IDH mutation, particularly IDH1 R132H detected by immunohistochemistry, plays an important role in tumor classification and prognosis. This study aimed to evaluate the value of multiparametric magnetic resonance imaging (MRI) in predicting IDH1 R132H mutation status in glioma patients. All patients underwent preoperative MRI including conventional sequences, diffusion-weighted imaging, and dynamic susceptibility contrast perfusion imaging. Quantitative parameters including apparent diffusion coefficient (ADC) and relative cerebral blood volume (rCBV) were measured in tumor and peritumoral regions and compared between the two groups. Receiver operating characteristic (ROC) analysis was used to evaluate diagnostic performance. The results showed that ADC and rCBV parameters measured in tumor regions were useful in predicting IDH mutation status, with tumor ADC demonstrating good diagnostic value. The combined model using diffusion and perfusion parameters provided better diagnostic performance than individual parameters. Multiparametric MRI may serve as a useful noninvasive method for predicting IDH mutation status in gliomas before surgery.
Article Details
Keywords
Glioma, IDH mutation, diffusion-weighted imaging, MRI Perfusion DSC, multiparametric MRI
References
2. Bộ Y tế. Hướng dẫn chẩn đoán và điều trị một số bệnh ung bướu - theo Bộ Y tế, Quyết định số 1514/QĐ-BYT ngày 01/04/2020 - Vietnam Regulatory Affairs Society - Luật Dược Việt Nam. Accessed June 12, 2025. https://vnras.com/huong-dan-chan-doan-va-dieu-tri-mot-so-benh-ung-buou-theo-bo-y-te-quyet-dinh-so-1514-qd-byt-ngay-01-04-2020/
3. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol (Berl). 2016;131(6):803-820.
4. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncol. 2021;23(8):1231-1251. doi:10.1093/neuonc/noab106
5. Byun YH, Park CK. Classification and Diagnosis of Adult Glioma: A Scoping Review. Brain NeuroRehabilitation. 2022;15(3):e23. doi:10.12786/bn.2022.15.e23
6. Zou P, Xu H, Chen P, et al. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PloS One. 2013;8(7):e68782. doi:10.1371/journal.pone.0068782
7. Villanueva-Meyer JE, Wood MD, Choi BS, et al. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis. Am J Roentgenol. 2018;210(3):621-628. doi:10.2214/AJR.17.18457
8. Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-Oncol. 2001;3(3):193-200. doi:10.1093/neuonc/3.3.193
9. Yang D, Korogi Y, Sugahara T, et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology. 2002;44(8):656-666. doi:10.1007/s00234-002-0816-9
10. Bhatti F, Strobel J, Tench C, et al. Apparent diffusion coefficient for genetic characterization of untreated adult gliomas: A meta-analysis stratified by methods. Neuro-Oncol Adv. 2025;7(1):vdaf103. doi:10.1093/noajnl/vdaf103
11. Cindil E, Sendur HN, Cerit MN, et al. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI. Acad Radiol. 2022;29:S52-S62. doi:10.1016/j.acra.2021.02.002
12. Sahu A, Patnam NG, Goda JS, et al. Multiparametric Magnetic Resonance Imaging Correlates of Isocitrate Dehydrogenase Mutation in WHO high-Grade Astrocytomas. J Pers Med. 2022;13(1):72. doi:10.3390/jpm13010072
13. Broen MPG, Smits M, Wijnenga MMJ, et al. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro-Oncol. 2018;20(10):1393-1399. doi:10.1093/neuonc/noy048
14. van Santwijk L, Kouwenberg V, Meijer F, et al. A systematic review and meta-analysis on the differentiation of glioma grade and mutational status by use of perfusion-based magnetic resonance imaging. Insights Imaging. 2022;13:102. doi:10.1186/s13244-022-01230-7
15. Tan WL, Huang WY, Yin B, et al. Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases. AJNR Am J Neuroradiol. 2014;35(5):920-927. doi:10.3174/ajnr.A3803
16. Hong EK, Choi SH, Shin DJ, et al. Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma. Eur Radiol. 2018;28(10):4350-4361. doi:10.1007/s00330-018-5400-8
17. Xing Z, Zhang H, She D, et al. IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region. Acta Radiol Stockh Swed 1987. 2019;60(12):1663-1672. doi:10.1177/0284185119842288
18. Losman JA, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339(6127):1621-1625. doi:10.1126/science.1231677
19. Xing Z, Yang X, She D, et al. Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging. AJNR Am J Neuroradiol. 2017;38(6):1138-1144. doi:10.3174/ajnr.A5171
20. Kickingereder P, Sahm F, Radbruch A, et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep. 2015;5:16238. doi:10.1038/srep16238